Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910713 · ClinicalTrials.gov registry record · NA
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
A NA study of Dry Eye Syndromes, sponsored by Allergan.
- Completed
- Registry status
- NA
- Development phase
- 185
- Enrollment target
- 3
- Study locations
NCT02910713: Completed NA study of Dry Eye Syndromes, sponsored by Allergan.
NCT02910713 is a NA study of Dry Eye Syndromes that has completed, run by Allergan. The registered enrollment target is 185 participants, below the 404-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (54% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02910713, a NA study of Dry Eye Syndromes, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- NA
- Development phase
- 185 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study evaluates the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally (active) compared with the same device applied extranasally (control) relating to symptoms of dry eye exacerbated by the Controlled Adverse Environment model.
Primary Outcome
The participant rated their eye dryness (both eyes simultaneously) at all visits and every 5 minutes during CAE exposure by placing a vertical mark on the 100 mm horizontal line to indicate the level of eye dryness. 0 corresponds to "no dryness" and 100 corresponds to "maximal dryness". A negative change from Baseline indicates improvement. A cross-over linear model was used with symptom relief as the response variable; sequence, application location, period, and the application location by peri
Conditions Studied
Interventions
- DEVICE Intranasal Tear Neurostimulator
Study Locations (3)
Tennessee
- Total Eye Care, PA - Memphis
- Nashville Vision Associates - Nashville
Kentucky
- Eye Care Institute - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2016-09-30 |
| Est. Completion | 2016-10-31 |
| Phase | NA |
What the finished NCT02910713 record still lists
NCT02910713 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, below the 404-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Dry Eye Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Intranasal Tear Neurostimulator is the first listed.
NCT02910713 reports a single indexed study location in Tennessee, Kentucky.
Frequently Asked Questions
What is clinical trial NCT02910713 about?
NCT02910713 is a clinical study titled "Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation". This study evaluates the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally (active) compared with the same device applied extranasally (control) relating to symptoms of dry eye exacerbated by the Controlled Adverse Environment model.
What is the current status of trial NCT02910713?
This trial is currently completed. It is a NA study. The enrollment target is 185 participants. The study started on 2016-09-30. Estimated completion is 2016-10-31.
What conditions does trial NCT02910713 study?
This clinical trial studies the following conditions: Dry Eye Syndromes.
What interventions are being tested in trial NCT02910713?
The interventions under investigation include: Intranasal Tear Neurostimulator (DEVICE).
Who is sponsoring clinical trial NCT02910713?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02910713 being conducted?
This trial has 3 study locations across Kentucky, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02910713's enrollment target sits among peer trials
185 7th of 17 higher than 11 of 17 other Dry Eye Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Applications of Advanced Ophthalmic Imaging
RECRUITING · NA
-
Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals
ACTIVE NOT RECRUITING · NA
-
TrueTear in Sjogren's Disease Patients
COMPLETED · NA
-
Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD
COMPLETED · NA
-
Corneal Epithelial Stem Cells and Dry Eye Disease
COMPLETED · NA
-
ACCURATE Study for Subjects With Dry Eyes
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05020860 · 185 participants · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI